Co.
Daiichi Sankyo and Merck Achieve Phase III Success with HER3-Targeted ADC in Lung Cancer
Patritumab deruxtecan, HER3-targeted ADC, Non-small cell lung cancer (NSCLC), Phase III trial, HERTHENA-Lung02, Daiichi Sankyo, Merck & Co.
ESMO 2023: Merck’s Welireg Demonstrates Sustained PFS Benefit in Advanced Renal Cell Carcinoma, Despite Ongoing OS Concerns
Merck & Co., Welireg (belzutifan), ESMO 2023, Advanced Renal Cell Carcinoma (RCC), Progression-Free Survival (PFS), Overall Survival (OS), LITESPARK-005 trial
WCLC24: Merck & Daiichi Sankyo’s ADC Shows Promising Results in Small Cell Lung Cancer
WCLC24, Merck & Co., Daiichi Sankyo, ADC (Antibody Drug Conjugate), SCLC (Small Cell Lung Cancer), Ifinatamab Deruxtecan, DXd ADC Technology
Merck & Co.’s Q1 Success Driven by Keytruda, Ups 2024 Outlook
Merck & Co., Q1 earnings, Keytruda, pharmaceuticals, cancer treatment, 2024 forecast